Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

Partner | Cancer Centers | <b>Sidney Kimmel Cancer Center at Jefferson</b>

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.

Suitable and tolerable treatments such as immunotherapy agents have changed the field of bladder cancer, says Hoffman-Censits, especially for patients who are ineligible for cisplatin.

Looking ahead, Hoffman-Censits says that recent advances with targeted therapy and immunotherapy will hopefully lead to longer survival and higher rates of bladder conservation.